Eli Lilly has begun its defence of a patent covering lung cancer drug Alimta against generic companies including Teva, Barr Laboratories and APP Pharmaceuticals.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Teva, Barr, APP, Alimta